Core Viewpoint - Serina Therapeutics is advancing its lead candidate SER-252 for advanced Parkinson's disease and has reported financial results for Q2 2025, highlighting growth in revenues and increased operating expenses due to R&D investments and administrative costs [1][3][4]. Financial Performance - Revenues for Q2 2025 were $130 thousand, up from $51 thousand in Q2 2024, entirely from NIH grant revenues [3]. - Operating expenses increased to $5.7 million in Q2 2025 from $3.9 million in Q2 2024 [3]. - R&D expenses rose to $3.2 million in Q2 2025, compared to $1.6 million in Q2 2024, driven by higher outside research services and increased headcount [4]. - General and administrative expenses were $2.5 million in Q2 2025, slightly up from $2.3 million in Q2 2024, mainly due to stock-based compensation and financial consulting expenses [5]. - The net loss for Q2 2025 was $6.4 million, or $(0.66) per share, compared to a net income of $5.2 million in Q2 2024 [8][22]. Liquidity and Funding - Cash and cash equivalents totaled $6.0 million as of June 30, 2025, projected to fund operations into Q4 2025 [9]. - In April 2025, Serina secured $5 million from strategic shareholders for the development of SER-252 and entered into a Capital on Demand™ Sales Agreement for an at-the-market offering program of $13.3 million [6]. Product Development - SER-252 is designed to provide continuous dopaminergic stimulation for Parkinson's disease and is expected to enter clinical trials in Q4 2025 [13]. - SER-270, a once-weekly injectable therapy for tardive dyskinesia, has been advanced, addressing unmet needs in treatment adherence [6][14]. Management and Board Updates - Dr. Stephen Brannan was appointed to the Board of Directors, bringing extensive experience in neuroscience and drug development [6].

Exhibit 99.1 Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights Operating expenses: Operating expenses for the three months ended June 30, 2025 and 2024 were $5.7 million and $3.9 million, respectively. • Advancement of SER-270 for Tardive Dyskinesia: In July 2025, Serina announced the advancement of SER-270 (POZ- VMAT2i), a once-weekly injectable therapy for tardive dyskinesia (TD), enabled by the POZ Platform. The program aims to address unment needs in TD t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 Serina Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1 ...

Group 1 - The article does not provide any specific company or industry insights, focusing instead on the author's qualifications and disclosures [1][2][3]

Core Insights - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications using its proprietary POZ Platform™ technology [2] Company Overview - Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [2] - The company is developing a pipeline of wholly owned drug product candidates aimed at improving the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [2] Upcoming Events - Steve Ledger, the CEO of Serina, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025, with his discussion set for July 29, 2025, at 2:00 p.m. ET [1]

Core Insights - Serina Therapeutics, Inc. is advancing its lead IND candidate SER-252 for advanced Parkinson's disease using its proprietary POZ Platform drug optimization technology [1][4] - The company granted options to purchase 12,500 shares of common stock to a new non-executive employee as an inducement for employment [1][2] - The exercise price for the options is set at the closing price of Serina's common stock on the date of the grant [2] Company Overview - Serina is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [4] - The POZ Platform aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates [4] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [4]

Core Points - Serina Therapeutics, Inc. has scheduled its 2025 annual meeting of stockholders for November 7, 2025 [1] - The deadline for stockholder proposals under Rule 14a-8 is set for August 15, 2025, due to the change in the meeting date [2] - Stockholder proposals and director nominations must be submitted in writing between July 10, 2025, and August 9, 2025, to be considered timely [3] Company Overview - Serina is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [4] - The company utilizes its POZ Platform to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [4] - Serina is headquartered in Huntsville, Alabama, at the HudsonAlpha Institute of Biotechnology [4]

Core Insights - Serina Therapeutics, Inc. is set to present its innovative drug optimization technology at a webinar focused on Parkinson's care, highlighting the limitations of current treatments and the potential of its proprietary drug candidate SER-252 [1][2][3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates aimed at treating neurological diseases and other indications, utilizing its proprietary POZ Platform for drug optimization [5] - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [5] Product and Technology - SER-252 is a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation (CDS), aiming for smoother and longer-lasting symptom control for Parkinson's patients [2] - The POZ Platform is a next-generation drug optimization system that has the potential to enhance the safety, duration, and tolerability of various therapeutics, including small molecules and RNA-based therapeutics [2][5] Event Details - The webinar titled "New Drug Optimization Platform to Transform Parkinson's Care" will take place on June 26, 2025, featuring a presentation by CEO Steve Ledger and a Q&A session for attendees [1][3]

Core Insights - Serina Therapeutics, Inc. has announced a strategic partnership with Juvenescence Ltd., which has successfully closed the first tranche of a $76 million Series B financing round, targeting a total of $150 million [2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the development of innovative therapeutics [3][4] - Serina is focused on developing its proprietary POZ Platform™ for drug optimization, targeting neurological diseases and other indications, and is positioned as a core portfolio company of Juvenescence [5][4] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, specializing in drug candidates for neurological diseases and other conditions [5] - The POZ Platform™ developed by Serina has the potential to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules and RNA-based therapeutics [5] - Juvenescence, the strategic partner, is an AI-enabled biotech company focused on developing medicines to extend healthy lifespan by targeting aging mechanisms [7][9] Strategic Partnerships - The collaboration between Juvenescence and M42, a global health company based in Abu Dhabi, signifies a commitment to building a leading life-sciences hub and developing a pipeline of innovative therapeutics [4][11] - M42 operates over 480 facilities across 26 countries and employs more than 20,000 people, integrating advanced technologies in healthcare [12]

Core Insights - Serina Therapeutics congratulates its strategic partner Juvenescence Ltd. for securing $150 million in Series B financing led by M42, which will enhance their drug development capabilities [1][2][3] - The partnership aims to establish a drug development hub in Abu Dhabi, integrating AI-enabled drug discovery with advanced clinical infrastructure to expedite the creation of innovative therapies targeting age-related diseases [2][3] - Juvenescence's leadership has a proven track record in biopharma, having previously led significant deals and developed medicines with peak annual sales totaling $30 billion [7][8] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its proprietary POZ Platform to enhance the efficacy and safety of various therapeutic modalities [4] - Juvenescence is an AI-enabled biotech company dedicated to extending healthy lifespan by targeting core aging mechanisms to treat age-related diseases [6][8] - M42, a global health company, combines AI, technology, and genomics to innovate healthcare solutions, operating over 480 facilities across 26 countries [9][11]